SEC 13F Intelligence

Managers / Q1 2020 · view latest →

SV Health Investors, LLC

CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100

Reported Value
$119M
Q1 2020
Positions
10
Filings on Record
16
2019–present window
Filed
May 15, 2020
original filing

Summary

Sv Health Investors, LLC reported $119M in U.S.-listed holdings across 10 positions for Q1 2020.

The portfolio is heavily concentrated: BCYC alone accounts for 21.9% of reported value.

The book was largely unchanged from Q4 2019.

Portfolio Metrics

Turnover
+6.1%
vs prior filed quarter
Top-10 Concentration
+100.0%
share of reported value
Largest Position
+21.9%
Bicycle Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $162MQ4 ’18Q1 ’19: $170MQ2 ’19: $149MQ2 ’19Q3 ’19: $142MQ4 ’19: $165MQ4 ’19Q1 ’20: $119MQ2 ’20: $144MQ2 ’20Q3 ’20: $197MQ4 ’20: $208MQ4 ’20Q1 ’21: $267MQ2 ’21: $230MQ2 ’21Q3 ’21: $204MQ4 ’21: $155MQ4 ’21Q1 ’22: $83MQ2 ’22: $44MQ2 ’22Q3 ’22: $32Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 46.3%Other: 31.7%ADR: 21.9%
  • Common Stock · 46.3% · $55M
  • Other · 31.7% · $38M
  • ADR · 21.9% · $26M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AVROBIO INCTRIMMED−181.1K1.24M−$9M$19M
KALVISTA PHARMACEUTICALS INCHELD+01.72M−$17M$13M
MISONIX, INC.HELD+01.70M−$16M$16M
DECIPHERA PHARMACEUTICALS INCHELD+0450.0K−$9M$19M
BCYCBICYCLE THERAPEUTICS PLCHELD+01.92M+$8M$26M
SUTRO BIOPHARMA INCHELD+01.82M−$1M$19M
OCULOCULAR THERAPEUTIX INCHELD+0628.2K+$628,000$3M
TRANSENTERIX INCHELD+0510.1K−$571,000$179,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

10 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS21.93%$26M1.92M
2AVROBIO INCCOM16.13%$19M1.24M
3SUTRO BIOPHARMA INCCOM15.61%$19M1.82M
4DECIPHERA PHARMACEUTICALS INCCOM15.54%$19M450.0K
5MISONIX, INC.COM13.40%$16M1.70M
6KALVISTA PHARMACEUTICALS INCCOM11.03%$13M1.72M
7X4 PHARMACEUTICALS INCCOM2.61%$3M311.5K
8OCULOCULAR THERAPEUTIX INChistory →COM2.61%$3M628.2K
9CATABASIS PHARMACEUTICALS INCOM NEW0.99%$1M285.8K
10TRANSENTERIX INCCOM NEW0.15%$179,000510.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$32M4Nov 7, 202213F-HRchanges · EDGAR ↗
Q2 2022$44M5Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$83M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M6Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$204M8Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$230M7Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$267M8May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$208M9Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$197M10Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$144M10Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$119M10May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M10Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M10Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$149M9Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$170M8May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$162M9Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 2 additional managers.

  • SVLSF VI, LLC028-19256
  • SV Life Sciences Fund VI (GP), L.P.028-19255

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.